Rare
lephants
Screener
Toggle theme
Vertex Pharmaceuticals Inc.
VRTX
·
Healthcare, Drug Manufacturers - General, United States
Analysis
Financial Statements
Profitability
Balance Sheet
Cash Flow
Price Ratios
Share-Based Metrics
Valuation
Cash Flow History
Net Cash Flow Breakdown
Net Cash Flow
Cash Flow
›
Net Cash Flow Breakdown
Net Cash Flow Breakdown
Chart
Table
FY2025
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2012
FY2011
Total Cash from Operations:
$913.3M
Line Item
Value
% of Total
Capital Expenditures
$23.5M
2.6%
Other Investing
$90.6M
9.9%
Other
$317.8M
34.8%
Net Cash Flow
$481.5M
52.7%
